Compare Humana Inc (HUM) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Global X Uranium ETF — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Global X Uranium ETF trades at $45.07. The key difference: Humana Inc pays a 0.92% dividend while Global X Uranium ETF pays none, and Humana Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| HUM | URA | |
|---|---|---|
Market Cap | $46.31B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $409.42 | $61.81 |
52-Week Low | $163.67 | $36.45 |
Enterprise Value | $53.67B | — |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
URA, the Global X Uranium ETF, trades at $44.91, up 3.96% in the past 24 hours. The ETF shows strong technical momentum with bullish signals from moving averages and oscillators, though the 6-day RSI at 92.80 indicates potential overbought conditions. Recent news highlights significant government support for nuclear energy, including a $17.5 billion commitment to new reactors and a landmark US-Saudi atomic deal, creating positive sentiment around uranium demand.
The outlook for URA remains positive due to growing nuclear energy adoption driven by AI power demands and supportive government policies. Key risks include ETF expense ratios and uranium price volatility. Analyst sentiment is generally bullish, with several recent articles recommending URA as a buy opportunity following its recent correction, citing long-term contract pricing improvements for uranium producers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
